World Psychiatry

, volume 22 , issue 1 , pages 48-74

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

Christoph U Correll ^{1, 2, 3, 4}

Marco Solmi ^{1, 5, 6, 7, 8}

Samuele Cortese ^{9, 10, 11, 12, 13}

Maurizio Fava ¹⁴

Mikkel Højlund ^{15, 16}

Helena C Kraemer ¹⁷

Roger S. McIntyre ^{18, 19, 20, 21, 22}

Daniel S. Pine ²³

Lon S. Schneider ²⁴

JOHN M. KANE ^{2, 3, 4}

Hide authors affiliations Show authors affiliations: 24 affiliations

Department of Child and Adolescent Psychiatry Charité Universitätsmedizin Berlin Berlin Germany |

Department of Psychiatry Zucker Hillside Hospital, Northwell Health Glen Oaks NY USA |

Department of Psychiatry and Molecular Medicine Zucker School of Medicine at Hofstra/Northwell Hempstead NY USA |

⁴

Center for Psychiatric Neuroscience Feinstein Institute for Medical Research Manhasset NY USA |

⁵

Department of Psychiatry University of Ottawa Ottawa ON Canada |

⁶

Department of Mental Health Ottawa Hospital Ottawa ON Canada |

⁷

Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa Ottawa ON Canada

University of Ottawa

Ottawa Hospital Research Institute

⁸

School of Epidemiology and Public Health, Faculty of Medicine University of Ottawa Ottawa ON Canada |

⁹

Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences University of Southampton Southampton UK |

¹⁰

Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine University of Southampton Southampton UK |

¹¹

Solent NHS Trust Southampton UK |

¹²

Division of Psychiatry and Applied Psychology, School of Medicine University of Nottingham Nottingham UK |

¹³

Hassenfeld Children's Hospital at NYU Langone New York University Child Study Center New York NY USA |

¹⁴

Depression Clinical and Research Program Massachusetts General Hospital, Harvard Medical School Boston MA USA

Harvard University

Massachusetts General Hospital

¹⁵

Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine University of Southern Denmark Odense Denmark |

¹⁶

Mental Health Services in the Region of Southern Denmark Department of Psychiatry Aabenraa Aabenraa Denmark |

¹⁷

Department of Psychiatry and Behavioral Sciences Stanford University Cupertino CA USA |

¹⁸

Mood Disorders Psychopharmacology Unit University Health Network Toronto ON Canada |

¹⁹

Institute of Medical Science University of Toronto Toronto ON Canada |

²⁰

Canadian Rapid Treatment Center of Excellence Mississauga ON Canada |

²¹

Department of Psychiatry University of Toronto Toronto ON Canada |

²²

Department of Pharmacology University of Toronto Toronto ON Canada |

²³

Section on Developmental Affective Neuroscience National Institute of Mental Health Bethesda MD USA |

²⁴

Department of Psychiatry and Behavioral Sciences, and Department of Neurology, Keck School of Medicine, and L. Davis School of Gerontology University of Southern California Los Angeles CA USA |

Publication type: Journal Article

Publication date: 2023-01-14

Wiley

World Psychiatry

scimago Q1

wos Q1

SJR: 18.419

CiteScore: 74.0

Impact factor: 65.8

ISSN: 17238617, 20515545

DOI: 10.1002/wps.21056

Copy DOI

PubMed ID: 36640403

Psychiatry and Mental health

Pshychiatric Mental Health

Found

1 citation

Galderisi Silvana

279 publications, 14 193 citations

h-index: 57

University of Campania "Luigi Vanvitelli"

Top-30

Journals

	2 4 6 8 10
World Psychiatry	World Psychiatry, 10, 10.99% World Psychiatry 10 publications, 10.99%
Molecular Psychiatry	Molecular Psychiatry, 4, 4.4% Molecular Psychiatry 4 publications, 4.4%
Journal of Psychiatric Research	Journal of Psychiatric Research, 3, 3.3% Journal of Psychiatric Research 3 publications, 3.3%
International Journal of Neuropsychopharmacology	International Journal of Neuropsychopharmacology, 3, 3.3% International Journal of Neuropsychopharmacology 3 publications, 3.3%
American Journal of Psychiatry	American Journal of Psychiatry, 3, 3.3% American Journal of Psychiatry 3 publications, 3.3%
Biological Psychiatry	Biological Psychiatry, 3, 3.3% Biological Psychiatry 3 publications, 3.3%
Pharmaceuticals	Pharmaceuticals, 3, 3.3% Pharmaceuticals 3 publications, 3.3%
Expert Opinion on Pharmacotherapy	Expert Opinion on Pharmacotherapy, 2, 2.2% Expert Opinion on Pharmacotherapy 2 publications, 2.2%
Neuroscience and Biobehavioral Reviews	Neuroscience and Biobehavioral Reviews, 2, 2.2% Neuroscience and Biobehavioral Reviews 2 publications, 2.2%
HRB Open Research	HRB Open Research, 2, 2.2% HRB Open Research 2 publications, 2.2%
CNS Drugs	CNS Drugs, 2, 2.2% CNS Drugs 2 publications, 2.2%
Expert Opinion on Drug Safety	Expert Opinion on Drug Safety, 2, 2.2% Expert Opinion on Drug Safety 2 publications, 2.2%
Psychiatry Research	Psychiatry Research, 2, 2.2% Psychiatry Research 2 publications, 2.2%
The Lancet Psychiatry	The Lancet Psychiatry, 2, 2.2% The Lancet Psychiatry 2 publications, 2.2%
Brain Sciences	Brain Sciences, 2, 2.2% Brain Sciences 2 publications, 2.2%
European Neuropsychopharmacology	European Neuropsychopharmacology, 2, 2.2% European Neuropsychopharmacology 2 publications, 2.2%
Expert Opinion on Emerging Drugs	Expert Opinion on Emerging Drugs, 2, 2.2% Expert Opinion on Emerging Drugs 2 publications, 2.2%
Processes	Processes, 1, 1.1% Processes 1 publication, 1.1%
Expert Review of Neurotherapeutics	Expert Review of Neurotherapeutics, 1, 1.1% Expert Review of Neurotherapeutics 1 publication, 1.1%
Expert Opinion on Drug Discovery	Expert Opinion on Drug Discovery, 1, 1.1% Expert Opinion on Drug Discovery 1 publication, 1.1%
Nature Reviews Disease Primers	Nature Reviews Disease Primers, 1, 1.1% Nature Reviews Disease Primers 1 publication, 1.1%
Cureus	Cureus, 1, 1.1% Cureus 1 publication, 1.1%
Biological Chemistry	Biological Chemistry, 1, 1.1% Biological Chemistry 1 publication, 1.1%
Current Opinion in Psychiatry	Current Opinion in Psychiatry, 1, 1.1% Current Opinion in Psychiatry 1 publication, 1.1%
BMJ Open	BMJ Open, 1, 1.1% BMJ Open 1 publication, 1.1%
The Lancet	The Lancet, 1, 1.1% The Lancet 1 publication, 1.1%
Nature Reviews Drug Discovery	Nature Reviews Drug Discovery, 1, 1.1% Nature Reviews Drug Discovery 1 publication, 1.1%
Australian and New Zealand Journal of Psychiatry	Australian and New Zealand Journal of Psychiatry, 1, 1.1% Australian and New Zealand Journal of Psychiatry 1 publication, 1.1%
International Journal of Psychiatry in Medicine	International Journal of Psychiatry in Medicine, 1, 1.1% International Journal of Psychiatry in Medicine 1 publication, 1.1%
	2 4 6 8 10

Publishers

	5 10 15 20 25
Elsevier	Elsevier, 21, 23.08% Elsevier 21 publications, 23.08%
Springer Nature	Springer Nature, 14, 15.38% Springer Nature 14 publications, 15.38%
Wiley	Wiley, 13, 14.29% Wiley 13 publications, 14.29%
Taylor & Francis	Taylor & Francis, 9, 9.89% Taylor & Francis 9 publications, 9.89%
MDPI	MDPI, 8, 8.79% MDPI 8 publications, 8.79%
Oxford University Press	Oxford University Press, 3, 3.3% Oxford University Press 3 publications, 3.3%
SAGE	SAGE, 3, 3.3% SAGE 3 publications, 3.3%
American Psychiatric Association Publishing	American Psychiatric Association Publishing, 3, 3.3% American Psychiatric Association Publishing 3 publications, 3.3%
F1000 Research	F1000 Research, 2, 2.2% F1000 Research 2 publications, 2.2%
Frontiers Media S.A.	Frontiers Media S.A., 2, 2.2% Frontiers Media S.A. 2 publications, 2.2%
Cambridge University Press	Cambridge University Press, 2, 2.2% Cambridge University Press 2 publications, 2.2%
Walter de Gruyter	Walter de Gruyter, 1, 1.1% Walter de Gruyter 1 publication, 1.1%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 1.1% Ovid Technologies (Wolters Kluwer Health) 1 publication, 1.1%
BMJ	BMJ, 1, 1.1% BMJ 1 publication, 1.1%
Research Square Platform LLC	Research Square Platform LLC, 1, 1.1% Research Square Platform LLC 1 publication, 1.1%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 1.1% Bentham Science Publishers Ltd. 1 publication, 1.1%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 1, 1.1% Cold Spring Harbor Laboratory 1 publication, 1.1%
Royal College of Psychiatrists	Royal College of Psychiatrists, 1, 1.1% Royal College of Psychiatrists 1 publication, 1.1%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 1.1% Public Library of Science (PLoS) 1 publication, 1.1%
American Medical Association (AMA)	American Medical Association (AMA), 1, 1.1% American Medical Association (AMA) 1 publication, 1.1%
Emerald	Emerald, 1, 1.1% Emerald 1 publication, 1.1%
Eco-Vector LLC	Eco-Vector LLC, 1, 1.1% Eco-Vector LLC 1 publication, 1.1%
	5 10 15 20 25

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Correll C. U. et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents // World Psychiatry. 2023. Vol. 22. No. 1. pp. 48-74.

GOST all authors (up to 50) Copy

Correll C. U., Solmi M., Cortese S., Fava M., Højlund M., Kraemer H. C., McIntyre R. S., Pine D. S., Schneider L. S., KANE J. M. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents // World Psychiatry. 2023. Vol. 22. No. 1. pp. 48-74.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1002/wps.21056

UR - https://doi.org/10.1002/wps.21056

TI - The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

T2 - World Psychiatry

AU - Correll, Christoph U

AU - Solmi, Marco

AU - Cortese, Samuele

AU - Fava, Maurizio

AU - Højlund, Mikkel

AU - Kraemer, Helena C

AU - McIntyre, Roger S.

AU - Pine, Daniel S.

AU - Schneider, Lon S.

AU - KANE, JOHN M.

PY - 2023

DA - 2023/01/14

PB - Wiley

SP - 48-74

IS - 1

VL - 22

PMID - 36640403

SN - 1723-8617

SN - 2051-5545

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2023_Correll,

author = {Christoph U Correll and Marco Solmi and Samuele Cortese and Maurizio Fava and Mikkel Højlund and Helena C Kraemer and Roger S. McIntyre and Daniel S. Pine and Lon S. Schneider and JOHN M. KANE},

title = {The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents},

journal = {World Psychiatry},

year = {2023},

volume = {22},

publisher = {Wiley},

month = {jan},

url = {https://doi.org/10.1002/wps.21056},

number = {1},

pages = {48--74},

doi = {10.1002/wps.21056}

}

MLA

Cite this

MLA Copy

Correll, Christoph U., et al. “The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents.” World Psychiatry, vol. 22, no. 1, Jan. 2023, pp. 48-74. https://doi.org/10.1002/wps.21056.

Publisher

Wiley

Journal

World Psychiatry

scimago Q1

wos Q1

SJR

18.419

CiteScore

74.0

Impact factor

65.8

ISSN

17238617 (Print)

20515545 (Electronic)